BioMarin Q3 top line up 18%, non-GAAP earnings up 29%

BioMarin Pharmaceutical (NASDAQ:BMRN) Q3 results:

Revenues: $461.1M (+17.7%); product sales: $450.9M (+16.7%).

Key product sales: Vimizim: $163.5M (+32.6%); PKU franchise: $144.7M (+23.4%); Naglazyme: $94.4M (-8.4%).

Net income: $55.0M (+536.5%); non-GAAP net income: $78.1M (+28.7%); EPS: $0.30 (+528.6%).

2019 guidance: Revenues: $1,680M – 1,750M from $1,690M – 1,720M; Vimizim: $530M – 570M from $540M – 570M; Kuvan: $420M – 460M from $455M – 475M; Naglazyme: $350M – 380M from $360M – 380M; net loss: ($85M – 45M); non-GAAP net income: $130M – 170M from $150M – 170M.

Previously: BioMarin Pharmaceutical EPS beats by $0.08, beats on revenue (Oct. 23)

https://seekingalpha.com/news/3508689-biomarin-q3-top-line-18-percent-non-gaap-earnings-29-percent